

Amendments to the Specification

Please replace the Title of the invention with the following rewritten title:

Bivalent *S. aureus* Type 5 and Type 8 Glycoconjugate Vaccines for Use in
Immune-Compromised Populations

Please replace paragraph number [0033] at page 11 with the following rewritten paragraph:

[0033] The vaccine according to the invention can be administered with or without an adjuvant. If an adjuvant is used, it is selected so as to avoid adjuvant-induced toxicity. A vaccine according to the present invention additionally may comprise a β -glucan or granulocyte colony stimulating factor, in particular, a β -glucan as described in U.S. application serial No. 09/395,360, filed September 14, 1999, now U.S. Patent No. 6,355,625.